Bertolt Kreft

Title: Bertolt Kreft: Innovator in Biopharmaceuticals

Introduction

Bertolt Kreft is a notable inventor based in Kleinmachnow, Germany. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative therapeutic agents. With a total of 2 patents to his name, Kreft's work focuses on addressing critical health issues through advanced scientific research.

Latest Patents

Kreft's latest patents include "Modified TNF-α antibodies and uses thereof." This patent relates to modified anti-TNFα polypeptides, their compositions, methods of making them, and their applications in treating diseases. Specifically, it emphasizes the treatment of inflammatory disorders using these modified polypeptides. Another significant patent is for "Substituted imidazoquinoxalines," which pertains to compounds that act as inhibitors of Mps-1 Kinase or TTK, showing potential in combating inflammation and cancer.

Career Highlights

Throughout his career, Kreft has worked with prominent companies in the pharmaceutical industry. Notable among these are Bright Peak Therapeutics AG and Bayer Intellectual Property GmbH. His work in these organizations has contributed to the advancement of therapeutic solutions in the medical field.

Collaborations

Kreft has collaborated with esteemed colleagues, including Vijaya Raghavan Pattabiraman and Rubén Alvarez Sanchez. These partnerships have fostered innovation and have been instrumental in the development of his patented technologies.

Conclusion

Bertolt Kreft stands out as an influential inventor in the biopharmaceutical sector, with a focus on innovative treatments for inflammatory disorders and cancer. His contributions through patents and collaborations continue to impact the field positively.